Patents Assigned to AERase, Inc.
-
Publication number: 20240009283Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: ApplicationFiled: January 26, 2023Publication date: January 11, 2024Applicant: Aerase, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: 11717562Abstract: A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.Type: GrantFiled: December 5, 2018Date of Patent: August 8, 2023Assignee: AERase, Inc.Inventors: Scott W. Rowlinson, Anthony G. Quinn, Ann Lowe, David Lowe
-
Publication number: 20210379167Abstract: Methods and compositions therefor of treating GAMT deficiency or guanidino acetate (GAA) toxicity in a subject comprising administration of an arginine depleting enzyme. An therapeutic formulation can include an arginase, an arginine deiminase or a combination thereof and optionally other compounds, and can be adapted for intravenous or subcutaneous administration to a subject.Type: ApplicationFiled: October 18, 2019Publication date: December 9, 2021Applicant: Aerase, Inc.Inventors: Anthony G. Quinn, Andreas Schulze, Scott W. Rowlinson
-
Publication number: 20210128703Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: ApplicationFiled: November 12, 2020Publication date: May 6, 2021Applicant: Aerase, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: 10729752Abstract: Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.Type: GrantFiled: September 8, 2017Date of Patent: August 4, 2020Assignee: AERASE, INC.Inventors: David Lowe, Scott W. Rowlinson, Susan Alters, Giulia Agnello
-
Publication number: 20190167770Abstract: A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.Type: ApplicationFiled: December 5, 2018Publication date: June 6, 2019Applicant: AERase, Inc.Inventors: Scott W. ROWLINSON, Anthony G. QUINN
-
Publication number: 20190000939Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: ApplicationFiled: July 16, 2018Publication date: January 3, 2019Applicant: AERASE, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: 10098933Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: GrantFiled: September 20, 2016Date of Patent: October 16, 2018Assignee: AERase, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: 9050340Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: GrantFiled: April 16, 2013Date of Patent: June 9, 2015Assignee: AERase, Inc.Inventors: George Georgiou, Everett Stone
-
Publication number: 20140242060Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: ApplicationFiled: May 12, 2014Publication date: August 28, 2014Applicant: AERASE, INC.Inventors: George GEORGIOU, Everett STONE
-
Patent number: 8679479Abstract: Methods and composition for generation of arginase variants with high serum persistence are provided. For example, in certain aspects methods for purifying pegylated arginase are described. Furthermore, the invention provides stabilized arginase multimers or pharmaceutical composition thereof.Type: GrantFiled: June 28, 2010Date of Patent: March 25, 2014Assignee: AERase, Inc.Inventors: George Georgiou, Everett Stone
-
Patent number: RE46423Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.Type: GrantFiled: May 14, 2015Date of Patent: June 6, 2017Assignee: AERASE, INC.Inventors: George Georgiou, Everett Stone
